HighTower Advisors LLC Sells 21,246 Shares of Axon Enterprise, Inc $AXON

HighTower Advisors LLC lessened its position in Axon Enterprise, Inc (NASDAQ:AXON) by 46.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,355 shares of the biotechnology company’s stock after selling 21,246 shares during the period. HighTower Advisors LLC’s holdings in Axon Enterprise were worth $13,832,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. NEOS Investment Management LLC raised its stake in Axon Enterprise by 82.7% during the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock worth $18,206,000 after buying an additional 11,482 shares during the period. Vanguard Group Inc. increased its holdings in shares of Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after acquiring an additional 376,904 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Axon Enterprise by 3.1% in the third quarter. Legal & General Group Plc now owns 421,114 shares of the biotechnology company’s stock worth $302,208,000 after acquiring an additional 12,736 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Axon Enterprise by 93.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 23,365 shares of the biotechnology company’s stock worth $13,270,000 after purchasing an additional 11,262 shares during the period. Finally, BIT Capital GmbH lifted its holdings in shares of Axon Enterprise by 75.6% during the 3rd quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company’s stock valued at $2,537,000 after purchasing an additional 1,522 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, Director Erika Nardini sold 198 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total transaction of $100,302.84. Following the completion of the sale, the director directly owned 1,946 shares in the company, valued at $985,804.68. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jeri Williams sold 157 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total value of $76,930.00. Following the sale, the director owned 1,159 shares of the company’s stock, valued at approximately $567,910. This represents a 11.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 13,855 shares of company stock worth $7,109,828. 4.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on AXON shares. William Blair reissued an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd. Weiss Ratings raised shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. The Goldman Sachs Group set a $535.00 price target on shares of Axon Enterprise in a research note on Thursday, May 7th. Barclays lowered their target price on Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $712.75.

Axon Enterprise Price Performance

AXON opened at $386.00 on Monday. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $885.91. The stock’s fifty day simple moving average is $416.52 and its 200 day simple moving average is $501.55. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. The stock has a market cap of $31.11 billion, a PE ratio of 155.02, a price-to-earnings-growth ratio of 7.02 and a beta of 1.44.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The firm had revenue of $807.35 million during the quarter, compared to analysts’ expectations of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.47 earnings per share. As a group, research analysts expect that Axon Enterprise, Inc will post 1.82 earnings per share for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.